ライフサイエンスコーパス: intravenous drug user

1 in a group of HCV- and HIV-negative, active intravenous drug users.

2 infective endocarditis (IE) is rare, even in intravenous drug users.

3 ith a subtly different variant of HIV-1 than intravenous drug users.

4 ding rapidly through new host populations of intravenous drug users.

5 ilities, those with prior MRSA exposure, and intravenous drug users.

6 tive gay men than in HIV-1-seronegative male intravenous drug users.

7 sequences and a well-known dual outbreak in intravenous drug users.

8 k heterosexuals, serodiscordant couples, and intravenous drug users.

9 who had sex with men, 0.38/100 PY among male intravenous drug users, 1.24/100 PY among female intrave

10 rom patients with haemophilia (1/84) or from intravenous drug users (2/63) had KSHV specific antibodi

11 as sex with men (2.7; 1.7-4.2), and being an intravenous drug user (3.8; 2.4-6.1) were all associated

12 ere initiated in MSM in 2018 (41.2%) than in intravenous drug users (35.6%).

13 ps, including plasmapheresis donors (34.0%), intravenous drug users (85.2%), and West African subject

14 patients (mean age, 42 years; 81% males; 46% intravenous drug users, 85.4% on ART) were analyzed.

15 HCV infection is highly prevalent among intravenous drug users, a population that is also at ris

16 luenced by certain HIV comorbidities such as intravenous drug user and hemophilia.

17 All were intravenous drug users and all but one were African-Amer

18 virus type 2 (HTLV-2), a common infection of intravenous drug users and subpopulations of Native Amer

19 avenous drug users, 1.24/100 PY among female intravenous drug users, and 1.13/100 PY among women at h

20 Blacks, Latinos, intravenous drug users, and less educated individuals ne

21 HTLV-2 infection is prevalent among intravenous drug users, and the viral genome encodes the

22 tandard tuberculin skin test (TST) among 467 intravenous drug users at risk for tuberculosis in urban

23 ses infecting a couple who were heterosexual intravenous drug users from Cyprus.

24 linked to the long-distance dispersion among intravenous drug users from the northwest.

25 over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and i

26 changes in men who have sex with men (MSMs), intravenous drug users (IDUs), hepatitis C virus (HCV)-i

27 loodborne viruses (95% in HCV-HIV coinfected intravenous drug users [IDUs]).

28 s endemic in several ethnic tribes and among intravenous drug users in metropolitan areas.

29 ample the likelihood of using organs from an intravenous drug user increased from 12.5% (4/24) with s

30 nt use of tobacco smoking among HIV-infected intravenous drug users (IVDUs), we set out to study the

31 sexual men, 5 HIV-positive heterosexual male intravenous drug users, or 5 healthy HIV-negative hetero

32 ll percentage of subtype B infections in the intravenous drug user populations.

33 disease in human immunodeficiency virus and intravenous-drug user populations are also causes for co

34 ently undergoing a serious HIV-1 epidemic in intravenous drug users, sex workers, and former plasma d

35 The outbreak began among intravenous drug users then spread to the general popula

36 for money or drugs, to have had sex with an intravenous drug user, to have sex when "high" on alcoho

37 ficiency virus-positive man who is an active intravenous drug user together with review of all publis

38 injection drug use, and sexual contact with intravenous drug users were higher by factors of 3 or mo

39 We present a case of a 43-year-old intravenous drug user who developed A. israelii infectio

40 eterosexuals, men who have sex with men, and intravenous drug users who are HIV infected yet suscepti

41 cting Mycobacterium tuberculosis exposure in intravenous drug users with or without human immunodefic

42 Valve excision is an option for intravenous drug users with tricuspid valve endocarditis

43 eld from targeted screening, particularly in intravenous drug users, would be substantially higher th